Almirall Hermal Germany
This sponsor has funded 3 studies across 1 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 25799 | Planned | Effectiveness and tolerability of the THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label... | No | No |
| 33014 | Planned | Effectiveness and tolerability of the THC:CBD oromucosal spray vs. dronabinol as add-on measure in patients with severe neuropathic pain:... | No | No |
| 38969 | Planned | Effectiveness and tolerability of the THC:CBD oromucosal spray vs. typical oral long-term opioid-analgesics in patients with severe neuropathic (low)... | No | No |
PAS by Risk Management Plan (RMP) requirement
Almirall Hermal Germany
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Almirall Hermal Germany
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Almirall Hermal Germany
1 Study countries specified are the following:
- Germany